Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase ii multicentre multinational study

This publication has 17 references indexed in Scilit:

• Aromatase inhibitors: current status and future applications
  Endocrine-Related Cancer, 1997
• Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: Clinical and endocrine effects
  European Journal Of Cancer, 1996
• New endocrine therapies for breast cancer
  European Journal Of Cancer, 1996
• Relations between sex hormones, sex hormone binding globulin, insulin-like growth factor-I and insulin-like growth factor binding protein-I in post-menopausal breast cancer patients
  Clinical Endocrinology, 1995
• Formestane
  Drugs, 1993
• Novel Irreversible Aromatase Inhibitors
  Annals of the New York Academy of Sciences, 1990
• Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy
  European Journal of Cancer and Clinical Oncology, 1989
• 6-Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): A new irreversible aromatase inhibitor
  Journal of Steroid Biochemistry, 1988
• The definition of the ‘no change’ category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast
  European Journal of Cancer and Clinical Oncology, 1988
• Mechanisms of Action of Aminoglutethimide as Endocrine Therapy of Breast Cancer
  Drugs, 1988